Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Moffett, Jenesse
IGNYTE, NCT03767348 / 2016-004548-12: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Jan 2024 - Mar 2024 : Data from IGNYTE trial in combination with Opdivo for 2L melanoma From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020 Nov 2020 - Nov 2020: From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020 Initial data from P1 portion of trial in combination with RP1 at SITC 2019 Nov 2019 - Nov 2019: Initial data from P1 portion of trial in combination with RP1 at SITC 2019	Recruiting	2	340	Europe, US	RP1, nivolumab, Opdivo	Replimune Inc., Bristol-Myers Squibb	Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC	12/25	12/28